Showing results (461-470 of 587) with videos related to

Sort By:
Pageof 59
Neuroendocrinology|August 17, 2017
Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter StudyFrancesca Marciello, Olaf Mercier, Piero Ferolla, et al.
The New England Journal of Medicine|April 30, 2015
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerPasi A Jänne, James Chih-Hsin Yang, Dong-Wan Kim, et al.
Cancers|August 7, 2021
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient TumorsEdouard Auclin, Perrine Vuagnat, Cristina Smolenschi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2025
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 TrialPasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, et al.
Science Advances|November 8, 2023
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLCMarie Naigeon, Matthieu Roulleaux Dugage, François-Xavier Danlos, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2021
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC networkArthur Petat, Eric Dansin, Fabien Calcagno, et al.
The Oncologist|April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 AnalysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist|May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2024
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung CancerJordi Remon, Benjamin Besse, Santiago Ponce Aix, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2024
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive reviewArthur Géraud, Thomas Hueso, Ariane Laparra, et al.
Pageof 59